Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-218195
Filing Date
2026-05-12
Accepted
2026-05-12 07:35:41
Documents
90
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sabs-20260331.htm   iXBRL 10-Q 3018875
2 EX-10.2 sabs-ex10_2.htm EX-10.2 19112
3 EX-31.1 sabs-ex31_1.htm EX-31.1 27033
4 EX-31.2 sabs-ex31_2.htm EX-31.2 27114
5 EX-32.1 sabs-ex32_1.htm EX-32.1 11641
6 EX-32.2 sabs-ex32_2.htm EX-32.2 11984
7 GRAPHIC img84486182_0.gif GRAPHIC 95030
  Complete submission text file 0001193125-26-218195.txt   14591787

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sabs-20260331.xsd EX-101.SCH 1877181
94 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20260331_htm.xml XML 3171984
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39871 | Film No.: 26965892
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)